AAPL331.34-1.74 (-0.52%) ▼|ABBV263.04+1.27 (+0.49%) ▲|ABT102.03-1.06 (-1.03%) ▼|ACN193.40-1.60 (-0.82%) ▼|ADBE257.76-7.84 (-2.95%) ▼|AMAT421.17-3.04 (-0.72%) ▼|AMD504.20+10.79 (+2.19%) ▲|AMGN375.65-5.85 (-1.53%) ▼|AMT177.71+0.77 (+0.44%) ▲|AMZN248.42-5.12 (-2.02%) ▼|AVGO339.27-5.45 (-1.58%) ▼|AXP324.43-3.35 (-1.02%) ▼|BA209.69-0.58 (-0.28%) ▼|BAC59.52+0.05 (+0.08%) ▲|BKNG171.32-4.03 (-2.30%) ▼|BLK1,058.66-6.94 (-0.65%) ▼|BMY63.73-0.37 (-0.58%) ▼|BNY154.67-2.99 (-1.90%) ▼|BRK-B516.76+1.81 (+0.35%) ▲|C136.17-0.01 (-0.01%) ▼|CAT783.54-0.46 (-0.06%) ▼|CL87.00-0.89 (-1.01%) ▼|CMCSA24.42-0.46 (-1.85%) ▼|COF206.85+0.17 (+0.08%) ▲|COP141.22+4.55 (+3.33%) ▲|COST901.35-17.56 (-1.91%) ▼|CRM255.65-3.78 (-1.46%) ▼|CSCO110.07+0.01 (+0.01%) ▲|CVS94.49-1.06 (-1.11%) ▼|CVX217.77+5.60 (+2.64%) ▲|DE684.04+2.58 (+0.38%) ▲|DHR209.36+6.11 (+3.01%) ▲|DIS106.42-2.17 (-2.00%) ▼|DUK117.77-1.25 (-1.05%) ▼|EMR147.00-1.30 (-0.88%) ▼|FDX308.26-4.31 (-1.38%) ▼|GD358.60+1.79 (+0.50%) ▲|GE307.05-10.51 (-3.31%) ▼|GEV882.81+8.05 (+0.92%) ▲|GILD146.30+0.71 (+0.49%) ▲|GM85.37-1.79 (-2.05%) ▼|GOOG341.43-4.28 (-1.24%) ▼|GOOGL344.98-4.41 (-1.26%) ▼|GS976.67-11.78 (-1.19%) ▼|HD305.48-5.39 (-1.73%) ▼|HON203.44+2.06 (+1.02%) ▲|IBM248.37-0.72 (-0.29%) ▼|INTC97.14-0.05 (-0.05%) ▼|INTU329.27-9.88 (-2.91%) ▼|ISRG377.16-0.78 (-0.21%) ▼|JNJ267.20+0.88 (+0.33%) ▲|JPM352.49+2.36 (+0.67%) ▲|KO88.71-0.11 (-0.12%) ▼|LIN462.96-1.45 (-0.31%) ▼|LLY1,136.11-2.17 (-0.19%) ▼|LMT533.46+4.08 (+0.77%) ▲|LOW194.61-3.56 (-1.80%) ▼|LRCX270.87-2.62 (-0.96%) ▼|MA573.27-1.15 (-0.20%) ▼|MCD252.78-4.71 (-1.83%) ▼|MDLZ62.10-0.29 (-0.46%) ▼|MDT93.75-0.05 (-0.05%) ▼|META670.24+4.64 (+0.70%) ▲|MMM164.67+2.65 (+1.64%) ▲|MO69.81+0.31 (+0.45%) ▲|MRK143.79-0.21 (-0.15%) ▼|MS206.28-0.30 (-0.15%) ▼|MSFT497.12-8.29 (-1.64%) ▼|MU927.60+3.57 (+0.39%) ▲|NEE81.07-0.56 (-0.69%) ▼|NFLX77.90-2.42 (-3.01%) ▼|NKE36.22-0.83 (-2.24%) ▼|NOW141.90-0.45 (-0.32%) ▼|NVDA212.17+1.21 (+0.57%) ▲|ORCL140.35-4.44 (-3.07%) ▼|PEP135.50-0.84 (-0.62%) ▼|PFE27.55-0.17 (-0.61%) ▼|PG146.67+0.54 (+0.37%) ▲|PLTR172.56-0.75 (-0.43%) ▼|PM194.11-0.75 (-0.38%) ▼|QCOM187.80+7.65 (+4.25%) ▲|RTX195.50+0.16 (+0.08%) ▲|SBUX96.58-2.49 (-2.51%) ▼|SCHW107.79+0.48 (+0.45%) ▲|SO85.95-1.05 (-1.21%) ▼|SPG204.10-0.87 (-0.42%) ▼|T26.72+0.21 (+0.79%) ▲|TMO641.39+28.24 (+4.61%) ▲|TMUS180.47-2.43 (-1.33%) ▼|TSLA356.58-2.39 (-0.67%) ▼|TXN263.43+0.01 (+0.00%) ▲|UBER71.43-1.20 (-1.65%) ▼|UNH375.93-7.62 (-1.99%) ▼|UNP283.99-1.09 (-0.38%) ▼|UPS102.35-0.11 (-0.11%) ▼|USB62.22-0.46 (-0.73%) ▼|V375.62+0.34 (+0.09%) ▲|VZ51.45+0.16 (+0.31%) ▲|WFC89.72+1.01 (+1.14%) ▲|WMT108.09-0.99 (-0.91%) ▼|XOM169.32+4.24 (+2.57%) ▲|AAPL331.34-1.74 (-0.52%) ▼|ABBV263.04+1.27 (+0.49%) ▲|ABT102.03-1.06 (-1.03%) ▼|ACN193.40-1.60 (-0.82%) ▼|ADBE257.76-7.84 (-2.95%) ▼|AMAT421.17-3.04 (-0.72%) ▼|AMD504.20+10.79 (+2.19%) ▲|AMGN375.65-5.85 (-1.53%) ▼|AMT177.71+0.77 (+0.44%) ▲|AMZN248.42-5.12 (-2.02%) ▼|AVGO339.27-5.45 (-1.58%) ▼|AXP324.43-3.35 (-1.02%) ▼|BA209.69-0.58 (-0.28%) ▼|BAC59.52+0.05 (+0.08%) ▲|BKNG171.32-4.03 (-2.30%) ▼|BLK1,058.66-6.94 (-0.65%) ▼|BMY63.73-0.37 (-0.58%) ▼|BNY154.67-2.99 (-1.90%) ▼|BRK-B516.76+1.81 (+0.35%) ▲|C136.17-0.01 (-0.01%) ▼|CAT783.54-0.46 (-0.06%) ▼|CL87.00-0.89 (-1.01%) ▼|CMCSA24.42-0.46 (-1.85%) ▼|COF206.85+0.17 (+0.08%) ▲|COP141.22+4.55 (+3.33%) ▲|COST901.35-17.56 (-1.91%) ▼|CRM255.65-3.78 (-1.46%) ▼|CSCO110.07+0.01 (+0.01%) ▲|CVS94.49-1.06 (-1.11%) ▼|CVX217.77+5.60 (+2.64%) ▲|DE684.04+2.58 (+0.38%) ▲|DHR209.36+6.11 (+3.01%) ▲|DIS106.42-2.17 (-2.00%) ▼|DUK117.77-1.25 (-1.05%) ▼|EMR147.00-1.30 (-0.88%) ▼|FDX308.26-4.31 (-1.38%) ▼|GD358.60+1.79 (+0.50%) ▲|GE307.05-10.51 (-3.31%) ▼|GEV882.81+8.05 (+0.92%) ▲|GILD146.30+0.71 (+0.49%) ▲|GM85.37-1.79 (-2.05%) ▼|GOOG341.43-4.28 (-1.24%) ▼|GOOGL344.98-4.41 (-1.26%) ▼|GS976.67-11.78 (-1.19%) ▼|HD305.48-5.39 (-1.73%) ▼|HON203.44+2.06 (+1.02%) ▲|IBM248.37-0.72 (-0.29%) ▼|INTC97.14-0.05 (-0.05%) ▼|INTU329.27-9.88 (-2.91%) ▼|ISRG377.16-0.78 (-0.21%) ▼|JNJ267.20+0.88 (+0.33%) ▲|JPM352.49+2.36 (+0.67%) ▲|KO88.71-0.11 (-0.12%) ▼|LIN462.96-1.45 (-0.31%) ▼|LLY1,136.11-2.17 (-0.19%) ▼|LMT533.46+4.08 (+0.77%) ▲|LOW194.61-3.56 (-1.80%) ▼|LRCX270.87-2.62 (-0.96%) ▼|MA573.27-1.15 (-0.20%) ▼|MCD252.78-4.71 (-1.83%) ▼|MDLZ62.10-0.29 (-0.46%) ▼|MDT93.75-0.05 (-0.05%) ▼|META670.24+4.64 (+0.70%) ▲|MMM164.67+2.65 (+1.64%) ▲|MO69.81+0.31 (+0.45%) ▲|MRK143.79-0.21 (-0.15%) ▼|MS206.28-0.30 (-0.15%) ▼|MSFT497.12-8.29 (-1.64%) ▼|MU927.60+3.57 (+0.39%) ▲|NEE81.07-0.56 (-0.69%) ▼|NFLX77.90-2.42 (-3.01%) ▼|NKE36.22-0.83 (-2.24%) ▼|NOW141.90-0.45 (-0.32%) ▼|NVDA212.17+1.21 (+0.57%) ▲|ORCL140.35-4.44 (-3.07%) ▼|PEP135.50-0.84 (-0.62%) ▼|PFE27.55-0.17 (-0.61%) ▼|PG146.67+0.54 (+0.37%) ▲|PLTR172.56-0.75 (-0.43%) ▼|PM194.11-0.75 (-0.38%) ▼|QCOM187.80+7.65 (+4.25%) ▲|RTX195.50+0.16 (+0.08%) ▲|SBUX96.58-2.49 (-2.51%) ▼|SCHW107.79+0.48 (+0.45%) ▲|SO85.95-1.05 (-1.21%) ▼|SPG204.10-0.87 (-0.42%) ▼|T26.72+0.21 (+0.79%) ▲|TMO641.39+28.24 (+4.61%) ▲|TMUS180.47-2.43 (-1.33%) ▼|TSLA356.58-2.39 (-0.67%) ▼|TXN263.43+0.01 (+0.00%) ▲|UBER71.43-1.20 (-1.65%) ▼|UNH375.93-7.62 (-1.99%) ▼|UNP283.99-1.09 (-0.38%) ▼|UPS102.35-0.11 (-0.11%) ▼|USB62.22-0.46 (-0.73%) ▼|V375.62+0.34 (+0.09%) ▲|VZ51.45+0.16 (+0.31%) ▲|WFC89.72+1.01 (+1.14%) ▲|WMT108.09-0.99 (-0.91%) ▼|XOM169.32+4.24 (+2.57%) ▲|
18.3 C
New York
Wednesday, September 16, 2026

Tag: exchange

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Freedom Holding Corp. Reports Fiscal Year 2025 Financial Results

ALMATY, Kazakhstan, June 15, 2025 /PRNewswire/ -- Freedom Holding Corp. (NASDAQ: FRHC), the diversified financial group with operations spanning 22 countries, today reported financial...

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

Scatec reaches financial close for the 1.1GW solar + 100MW/200MWh BESS Obelisk project

Oslo/Cairo, 15 June 2025: Scatec ASA has reached financial close for the “Obelisk” hybrid solar and battery storage project in Egypt.

Scatec signs PPA for 900MW onshore wind project in Egypt

Oslo/Cairo, 15 June 2025: Scatec ASA, a leading renewable energy solutions provider, has signed a USD-denominated 25-year Power Purchase Agreement (PPA) with the Egyptian Electricity Transmission Company (EETC) for a 900 MW wind project, through its dedicated project company “Shadwan Wind Power SAE” to accelerate Egypt’s transition towards a greener and more sustainable energy mix.

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Translational Data Presented at EACCI Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Eve Air Mobility and Revo Accelerate Urban Air Mobility with $250M Contract

A fleet of up to 50 aircraft and aftermarket services is poised to revolutionize urban transport across Revo's key markets. PARIS, June 15, 2025 /PRNewswire/ -- Eve Air Mobility ("Eve") (NYSE: EVEX) (NYSE: EVEXW) has signed its first binding framework agreement with...

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

China, Central Asia make continuous efforts to deepen agricultural cooperation

BEIJING, June 15, 2025 /PRNewswire/ -- A report from People's Daily: ...

Eve Air Mobility Twenty-Year Market Outlook Highlights Growth of Urban Air Mobility Globally

Outlook highlights a $280 billion passenger revenue and 30,000 aircraft opportunities driven by urban population growth, traffic concerns, and a commitment to sustainability. PARIS,...

Nimanode Surpasses Crypto Presales, Eyes 10X Growth Post-Launch as Major Investors Flock to the XRP DeFi Landscape

LEEDS, United Kingdom, June 14, 2025 (GLOBE NEWSWIRE) -- Nimanode, the first no-code AI agent platform built natively on the XRP Ledger (XRPL), is gaining momentum with its ongoing $NMA token presale.

No KYC. 100x Leverage. $50 Welcome Bonus. Crypto Futures Trading Made Easy on BexBack.

SINGAPORE, June 14, 2025 (GLOBE NEWSWIRE) -- With the price of Bitcoin fluctuating around $100,000, many analysts predict that the cryptocurrency market will remain in a state of high volatility for a long time. Holding spot positions may struggle to generate short-term profits in such conditions. As a result, 100x leverage futures trading has become the preferred tool for seasoned investors looking to maximize potential gains in this volatile market. BexBack Exchange is ramping up its efforts to offer traders unmatched promotional packages. The platform now features a 100% deposit bonus, a $50 welcome bonus for new users, and 100x leverage on cryptocurrency trading, providing exceptional opportunities for investors.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsExchange